文献

J-GLOBAL ID：202202245607281124   整理番号：22A0328435

重症筋無力症はボツリヌス毒素の禁 contraか?【JST・京大機械翻訳】

Is myasthenia gravis a contraindication for botulinum toxin?

著者 (27件)： Ma Qian (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Ma Qian (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Ran Hao (School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China) ,  Ou Changyi (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Ou Changyi (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Liu Xiaoxi (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Liu Xiaoxi (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Lu Yaru (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Lu Yaru (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Huang Huan (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Huang Huan (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Yang Wenhao (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Yang Wenhao (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Yu Lu (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Yu Lu (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Chen Pei (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Chen Pei (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Huang Xin (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Huang Xin (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Qiu Li (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Qiu Li (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Lin Zhongqiang (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Lin Zhongqiang (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Huang Zhidong (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Huang Zhidong (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Liu Weibin (Department of Neurology, The First Affiliated Hospital, Sun Yat-sen University, No. 58 Zhongshan Road 2, Guangzhou 510080, China) ,  Liu Weibin (Guangdong Provincial Key Laboratory of Diagnosis and Treatment of Major Neurological Diseases, National Key Clinical Department and Key Discipline of Neurology, No. 58 Zhongshan Road 2, Guangzhou 510080, China)
資料名： Journal of Clinical Neuroscience  (Journal of Clinical Neuroscience)
巻： 95  ページ： 44-47  発行年： 2022年 
JST資料番号： W3362A  ISSN： 0967-5868  資料種別： 逐次刊行物 (A)
記事区分： 文献レビュー  発行国： オランダ (NLD)  言語： 英語 (EN)

抄録/ポイント： ボツリヌス毒素(BTX)は様々な疾患を治療するために使用されてきた神経毒であり,伝統的に,重症筋無力症(MG)はBTXに対する禁忌と考えられている。BTXがMG患者において避けるべきであるかどうかを決定するために,著者らのMGとジストニアスペシャリストクリニックからの臨床データを遡及的に分析した。さらに,MGとBTX処理の共存に関連するすべての公表症例を同定するために,系統的文献レビューを行った。ここでは,MG診断前にBTX注射を受けた,著者らのクリニックからの1人の患者を述べた。文献レビュー後,ジストニアまたは化粧品理由(MG診断前のBTX注射)のためにBTXで以前に治療された潜在性MGの8症例を同定した。8名中8名(100%)が明らかな筋力低下を発症した。対照的に,共存症としてMGを示す10人の患者は,ジストニアまたは過活動膀胱(MG診断後のBTX注射)に対しBTXを受け,10人中8人(80%)はBTX注射を受ける前に適切な用量修正とMGに対する適切な治療を介し改善した症状を経験した。これらの知見は,共存MGの適切な管理の下で,BTXが,将来,MG共存症を呈する患者において,安全かつ首尾よく使用できることを支持する。Copyright 2022 Elsevier B.V., Amsterdam. All rights reserved. Translated from English into Japanese by JST.【JST・京大機械翻訳】

シソーラス用語： 化粧品 ,  神経毒 ,  文献展望 ,  診断 ,  症状 ,  用量 ,  *ボツリヌス毒素 ,  ジストニア ,  *重症筋無力症 ,  筋力低下
準シソーラス用語： 共存罹患 ,  臨床データ , 【Automatic Indexing@JST】

著者キーワード (3件)： ボツリヌス毒素 ,  重症筋無力症 ,  禁 Contra

分類 (2件)： 神経の臨床医学一般  (GN01030H) ,  神経系疾患の治療一般  (GN05010N)

タイトルに関連する用語 (2件)： 重症筋無力症 ,  ボツリヌス毒素